Lonza Builds Oregon Spray-Drying Facility To Expand SDD Capacity

Spray-dried dispersion capacity at commercial scale has been a persistent bottleneck for CDMOs handling poorly soluble compounds, and Lonza's decision to build a major spray-drying facility in Bend, Oregon moves the needle on that constraint. The investment directly targets amorphous solid dispersion (ASD) manufacturing, a technology increasingly specified in outsourced development programs where bioavailability enhancement is a formulation requirement.

The Bend site is positioned by Lonza as an integrated node within its broader development and manufacturing network, designed to support end-to-end services for spray-dried dispersions (SDDs). For QA directors and plant heads evaluating CDMO partnerships, that integration claim carries process validation implications: seamless tech transfer between development-scale and commercial-scale spray-drying units requires documented equivalence studies and robust ICH Q10-aligned pharmaceutical quality systems across both sites.

From a regulatory affairs standpoint, commercial spray-drying facilities operating under 21 CFR Part 211 face specific scrutiny around particle size distribution controls, residual solvent limits, and in-process monitoring for amorphous content. A new-build facility offers Lonza the opportunity to design those controls into the manufacturing environment from the ground up, rather than retrofitting existing infrastructure, a meaningful advantage when supporting NDA or ANDA submissions that reference the site.

The broader CDMO market context is relevant here. Demand for ASD-based formulations has grown in step with the increasing proportion of BCS Class II and IV compounds in development pipelines. Outsourced spray-drying capacity, particularly at commercial scale, has not kept pace. Lonza's Oregon expansion signals a calculated response to that supply-demand gap, and competing CDMOs with ASD capabilities will need to assess whether their own commercial-scale footprints remain competitive.

The facility's readiness timeline and the regulatory filing strategy for the Bend site will be the next measurable indicators of how quickly this capacity translates into available commercial slots for sponsors.

Source: Media4Growth via Indian Pharma Post, 10 September 2026.